University of Bergen, Department of Clinical Science , Bergen , Norway.
Expert Opin Ther Targets. 2014 Nov;18(11):1237-51. doi: 10.1517/14728222.2014.957671. Epub 2014 Sep 9.
The malignant cell population of acute myeloid leukemia (AML) includes a small population of stem/progenitor cells with long-term in vitro proliferation. We wanted to compare long-term AML cell proliferation for unselected patients, investigate the influence of endothelial cells on AML cell proliferation and identify biological characteristics associated with clonogenic capacity.
Cells were cultured in medium supplemented with recombinant growth factors FMS-like tyrosine kinase-3 ligand, stem cell factor, IL-3, G-CSF and thrombopoietin. The colony-forming unit assay was used to estimate the number of progenitors in AML cell populations after 35 days of culture, and microarray was used to study global gene expression profiles between AML patients.
Long-term cell proliferation was observed in 7 of 31 patients, whereas 3 additional patients showed long-term proliferation after endothelial cell coculture. Patient-specific differences in constitutive cytokine release were maintained during cell culture. Patients with long-term proliferation showed altered expression in six cell cycle-related genes (HMMR, BUB1, NUSAP1, AURKB, CCNF, DLGAP5), two genes involved in DNA replication (TOP2A, RFC3) and one gene with unknown function (LHFPL2).
We identified a subset of AML patients characterized by long-term in vitro cell proliferation and altered expression of cell cycle regulators that may be potential candidates for treatment of AML.
急性髓系白血病(AML)的恶性细胞群体包括一小部分具有长期体外增殖能力的干细胞/祖细胞。我们希望比较未经选择的患者的长期 AML 细胞增殖情况,研究内皮细胞对 AML 细胞增殖的影响,并确定与集落形成能力相关的生物学特征。
将细胞在补充有重组生长因子 FMS 样酪氨酸激酶-3 配体、干细胞因子、IL-3、G-CSF 和血小板生成素的培养基中培养。使用集落形成单位测定法估计 AML 细胞群体在 35 天培养后的祖细胞数量,并使用微阵列研究 AML 患者之间的全基因表达谱。
31 例患者中有 7 例观察到长期细胞增殖,而另外 3 例在与内皮细胞共培养后表现出长期增殖。细胞培养过程中维持了患者固有细胞因子释放的个体差异。长期增殖的患者表现出六个细胞周期相关基因(HMMR、BUB1、NUSAP1、AURKB、CCNF、DLGAP5)、两个参与 DNA 复制的基因(TOP2A、RFC3)和一个功能未知的基因(LHFPL2)的表达改变。
我们鉴定了一组 AML 患者,其特征为长期体外细胞增殖和细胞周期调节剂表达改变,这些患者可能是 AML 治疗的潜在候选者。